M2 Pharma - Therapy Areas

Tetraphase Pharmaceuticals Launches Corporate Reorganisation

17 June 2019 - - US-based Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) has launched a corporate reorganisation in order to maximise the commercial opportunity for Xerava (eravacycline), the co...

Valo Therapeutics names new chief executive officer

17 June 2019 - Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, announced today that it has named Dr Michael Stein as i...

US FDA grants approval to Amgen and Allergan's Kanjinti

17 June 2019 - The US Food and Drug Administration (FDA) has granted approval to US-based Amgen and Ireland-based Allergan for its Kanjinti (trastuzumab-anns), a biosimilar to Roche's Herceptin (...

Valo Therapeutics names Michael Stein as CEO

17 June 2019 - Cancer immunotherapy company Valo Therapeutics Limited stated on Monday that Dr Michael Stein, PhD, MD, has been elected to the full-time role of chief executive officer.Prior to the ne...

Elthera wins EUR2.5m grant from Horizon 2020 Programme

17 June 2019 - Swiss biotechnology company Elthera reported on Monday the receipt of EUR2.5m through the Horizon 2020 programme.Horizon 2020 is the financial instrument implementing the Innovation Uni...

Oncopeptides to present new data from phase 1/2 ANCHOR trail at 24th EHA Congress

17 June 2019 - Oncopeptides AB (STO:ONCO) on Friday announced the presentation of new data at the 24th Congress of the European Haematology Association (EHA) in Amsterdam, including updated interim da...